Skip to content

In the BioHarmony Drug Report Database

Idarucizumab

Praxbind (idarucizumab) is an antibody pharmaceutical. Idarucizumab was first approved as Praxbind on 2015-10-16. It has been approved in Europe to treat hemorrhage.
Trade Name Praxbind
Common Name Idarucizumab
Indication hemorrhage
Drug Class Monoclonal antibodies: humanized, cardiovascular indications
Idarucizumab
Get full access now